Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

Sponsor
General Committee of Teaching Hospitals and Institutes, Egypt
Study ID
NCT05285397
Status
Unknown

Conditions

  • Morbid Obesity

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.

Key Dates

Start date
Mar 10, 2022
Status verified
Mar 2022
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    drug starts 6 weeks post-operative until 6 months SC injection dose starting 0.6 mg/day and weekly up titrated until 3.0 mg/day
  • No Intervention: Control
    Patients with no weight loss drug intervention after bariatric surgery

Primary Outcome Measure

Percentage Total weight loss [ Time Frame: 6 months ]

Central Contacts

Related Studies